These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16466035)

  • 1. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala.
    Okwera A; Johnson JL; Luzze H; Nsubuga P; Kayanja H; Cohn DL; Nunn P; Ellner JJ; Whalen CC; Mugerwa RD
    Int J Tuberc Lung Dis; 2006 Jan; 10(1):39-44. PubMed ID: 16466035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration.
    Johnson JL; Okwera A; Nsubuga P; Nakibali JG; Whalen CC; Hom D; Cave MD; Yang ZH; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 2000 Nov; 4(11):1032-40. PubMed ID: 11092715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
    Jindani A; Nunn AJ; Enarson DA
    Lancet; 2004 Oct 2-8; 364(9441):1244-51. PubMed ID: 15464185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
    Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
    Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.
    Johnson JL; Okwera A; Vjecha MJ; Byekwaso F; Nakibali J; Nyole S; Milberg J; Aisu T; Whalen CC; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):446-53. PubMed ID: 9441100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis.
    Nunn AJ; Jindani A; Enarson DA;
    Int J Tuberc Lung Dis; 2011 Jun; 15(6):741-5. PubMed ID: 21575292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
    Okwera A; Whalen C; Byekwaso F; Vjecha M; Johnson J; Huebner R; Mugerwa R; Ellner J
    Lancet; 1994 Nov; 344(8933):1323-8. PubMed ID: 7526098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis.
    Schwander S; Rüsch-Gerdes S; Mateega A; Lutalo T; Tugume S; Kityo C; Rubaramira R; Mugyenyi P; Okwera A; Mugerwa R
    Tuber Lung Dis; 1995 Jun; 76(3):210-8. PubMed ID: 7548903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG).
    el-Sadr WM; Perlman DC; Matts JP; Nelson ET; Cohn DL; Salomon N; Olibrice M; Medard F; Chirgwin KD; Mildvan D; Jones BE; Telzak EE; Klein O; Heifets L; Hafner R
    Clin Infect Dis; 1998 May; 26(5):1148-58. PubMed ID: 9597244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
    Gopalan N; Santhanakrishnan RK; Palaniappan AN; Menon PA; Lakshman S; Chandrasekaran P; Sivaramakrishnan GN; Reddy D; Kannabiran BP; Agiboth HKK; Krishnamoorthy V; Rathinam S; Chockalingam C; Manoharan T; Ayyamperumal M; Jayanthi N; Satagopan K; Narayanan R; Krishnaraja R; Sathiyavelu S; Kesavamurthy B; Suresh C; Selvachitiram M; Arasan G; Susaimuthu S; Rathinam P; Angamuthu P; Jayabal L; Murali L; Ramachandran R; Tripathy SP; Swaminathan S
    JAMA Intern Med; 2018 Apr; 178(4):485-493. PubMed ID: 29507938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa.
    Connolly C; Reid A; Davies G; Sturm W; McAdam KP; Wilkinson D
    AIDS; 1999 Aug; 13(12):1543-7. PubMed ID: 10465079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda.
    Joloba ML; Whalen CC; Cave DM; Eisenach KD; Johnson JL; Okwera A; Morrissey A; Bajaksouzian S; Feagin J; Mugerwa R; Ellner J; Jacobs MR
    East Afr Med J; 2000 Feb; 77(2):111-5. PubMed ID: 10774085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis.
    Bartacek A; Schütt D; Panosch B; Borek M;
    Int J Tuberc Lung Dis; 2009 Jun; 13(6):760-6. PubMed ID: 19460254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.